In preclinical models of SLE, anti-CD19 CAR T-cell therapy has been shown to induce sustained depletion of CD19+ B cells, clear renal inflammation, and significantly extend the lifespan of model mice. This evidence concerns the gene CD19 and systemic lupus erythematosus.